Free Trial

PureTech Health (LON:PRTC) Trading Up 14.2% - Time to Buy?

PureTech Health logo with Medical background

Key Points

  • PureTech Health's stock experienced a significant rise of 14.2%, closing at GBX 121.50 ($1.64) with a high of GBX 123.80 during trading.
  • The company's trading volume surged by 1,053%, with approximately 9 million shares changing hands compared to an average of around 781,000 shares.
  • Insider Bharatt Chowrira bought 167,739 shares at an average price of GBX 1 per share, indicating confidence in the company's prospects, with insiders owning 13.13% of the stock.
  • MarketBeat previews the top five stocks to own by October 1st.

Shares of PureTech Health plc (LON:PRTC - Get Free Report) rose 14.2% on Friday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares were traded during trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Trading Up 4.2%

The stock has a fifty day moving average of GBX 129.46 and a 200 day moving average of GBX 129.72. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68. The company has a market capitalization of £303.07 million, a PE ratio of 737.65 and a beta of 1.02.

Insider Buying and Selling

In other PureTech Health news, insider Bharatt Chowrira purchased 167,739 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were bought at an average cost of GBX 1 per share, with a total value of £1,677.39. Corporate insiders own 13.13% of the company's stock.

PureTech Health Company Profile

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

See Also

Should You Invest $1,000 in PureTech Health Right Now?

Before you consider PureTech Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.

While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.